SAN ANTONIO—Merck & Co.’s Keytruda and Roche’s Tecentriq are battling for immuno-oncology supremacy in an ever-growing range of indications. But in hard-to-treat triple-negative breast cancer (TNBC), Keytruda’s latest data came out on top.
Adding Keytruda to standard-of-care chemotherapy ahead of surgery delivered pathologic complete responses—a lack of cancer cells in surgically removed tissue––in 64.8% of newly diagnosed TNBC patients whose disease had spread to the lymph nodes, a new subanalysis shows. Just 44.1% of those treated with chemo alone could say the same.
Drawn from Keytruda’s phase 3 Keynote-522 study, the subgroup data were presented Thursday at the San Antonio Breast Cancer Symposium. They back up top-line numbers released in September showing a Keytruda-chemo combo achieved a pathologic complete response in 64.8% of the study’s patients compared with 51.2% on chemo alone.
Overall, patients in the Keynote-522 study also showed a 37% risk reduction in disease recurrence after surgery compared with solo chemo, a result that wasn’t statistically significant.
twisted family secrets full movie limpiando culo snigdha sinha video anyxvideos.com sex slave full video view here ksb besaba com katrina reyal sex garden on house wife rape 1st sex young xnxx-br.com bd bdsexvideo sasur bhou sex romance bluepornsex video xxx vide0 gan czech teen swallow money گایدن افقانی anushka sharma ki video vdeo xxx japaeb fetishwife clare